In obstetric emergencies, minutes matter because outcomes depend on time-critical access to blood products, operating room availability, anesthesia support, intensive care unit (ICU) capacity, interfacility transfer, and high-acuity monitoring (1). Protocols for postpartum hemorrhage, hypertensive crises, and maternal sepsis are intended to standardize recognition and escalation (2–5). However, comparable clinical risk does not consistently translate into comparable speed or intensity of response. Queues and handoffs—triage thresholds, paging cascades, transport logistics, and competing cases—can delay definitive care even when the diagnosis is clear (1). The paradox is that many gaps reflect workflow design and access constraints rather than missing medical knowledge (3, 4).

Equity in artificial intelligence (AI)-supported obstetric emergency care is not a model attribute (e.g., area under the receiver operating characteristic curve [AUC] or calibration); rather, it is whether deployment translates risk signals into timely escalation, resource readiness, and safer disposition for patients presenting with similar risk (6, 7). In practice, deployed tools fail at three predictable breakpoints: a trigger that is not acted on, an action that does not mobilize resources, and resources that arrive too late to alter outcomes (7). Audits that end at model performance can therefore validate a statistically strong tool while allowing inequity to be produced by unclear ownership, capacity bottlenecks, and fragmented handoffs (6). Evaluation should follow the chain of care, quantify step-specific delays and denials, and test whether breakdowns and prolonged intervals cluster within particular groups and contexts (7).

This perspective provides three deliverables: (i) a service-chain framework that specifies where inequity can emerge after deployment; (ii) a Minimum Fairness Audit Set (MFAS) dashboard designed to be low-burden and auditable; and (iii) a worked application in postpartum hemorrhage (PPH), hypertensive crises/eclampsia, and obstetric sepsis (1, 3, 4). We use World Health Organization pathway standardization as an anchor to define expected trigger-to-treatment transitions and then generalize the audit logic to adjacent obstetric emergencies without overextending what guidelines can legitimately support (1).

PPH care has evolved from subjective estimation toward quantified assessment that is explicitly linked to predefined treatment bundles, aligning measurement, pathway activation, and early treatment within a single operational toolchain (2, 8, 9). World Health Organization guidance pairs structured blood-loss assessment with a treatment bundle, operationalizing a “quantify-then-treat” approach rather than reliance on variable, clinician-specific thresholds (8). This consolidated pathway logic further embeds diagnosis and treatment within higher-quality perinatal care, implying stocked supplies, defined roles, and standardized handoffs rather than ad hoc escalation (1). Contemporary guidance also underscores that timely access to non-surgical hemorrhage-control devices constitutes a pathway-critical node (10). In practice, bundle implementation commonly fails at toolchain interfaces—when quantification does not trigger action, or when activation cannot reliably mobilize resources. For equity-focused evaluation, audits should therefore treat device readiness, blood-product access, operating room availability, and staffing capacity as measurable nodes and not merely verify that a “bundle” exists in policy documents (2).

Work on obstetric sepsis has converged on a two-step process: screening for risk and then confirming with focused evaluation and initiating escalation pathways that bundle diagnostics, antibiotics, fluids, and higher-acuity clinical review (4, 11). Toolkits operationalize this approach by packaging criteria, checklists, reassessment intervals, and escalation prompts to improve reliability across handoffs and shifts (11). Screening thresholds remain operationally consequential: increasing sensitivity can amplify false-positive alerts and workload, whereas missed cases delay escalation and definitive treatment (12). Equity-relevant evaluation, therefore, requires linking triggers to treatment timing and escalation completion rather than validating the screening instrument in isolation (4).

These advances increasingly standardize “what to do,” yet many systems do not routinely audit who is triggered, who receives rapid response, and whether time-critical resources are actually made ready when escalation is signaled (2, 6, 7). Early warning scores can harmonize recognition and escalation pathways, but equity depends on the reliability of downstream response and resource readiness across units, shifts, and entry routes into care (13). The persisting gap is routine post-deployment measurement of stratified delays and denials at the point of care—an audit layer that renders failures visible, attributable, and correctable (6).

Model-layer metrics (AUC, calibration) quantify discrimination and fit within a dataset; they do not test whether deployment reliably translates risk signals into timely escalation and resource readiness at the bedside (7, 14). In obstetric emergencies, similar underlying clinical risks can enter the system through heterogeneous data pipelines and operational contexts—missing inputs, delayed documentation, variable monitoring intensity, and site- or shift-specific data streams—thereby changing when (or whether) an alert is generated, displayed, and owned (15, 16). Even when a trigger is produced, downstream performance is shaped by access frictions and operational constraints: language discordance, payer rules, and referral pathways can influence senior review and transfer acceptance, while blood bank, OR, and ICU capacity determine whether activation yields resource-ready timeframes (6). Fairness should therefore be assessed at the service layer after deployment by auditing the chain of care—Trigger → Response → Resource-ready/arrival → Disposition → Outcomes—so that disparities can be localized to a specific link and paired with actionable workflow, communication, or capacity levers rather than inferred from model performance alone (6, 14).

Figure 1 summarizes MFAS as an audit-to-action instrument linking stratified delay gaps to remediable workflow, communication, and capacity levers.

Equality applies identical thresholds; equity aims to ensure comparable opportunities to receive time-critical care when risk is similar at presentation (7, 14). In obstetric emergencies, the most operational equity target is to reduce stratified gaps in avoidable delay, because delay is the mechanism through which triage, escalation, and resource contention translate into harm (17). We define avoidable delay as any chain-of-care interval (from trigger to key actions/resources) that exceeds a prespecified target window within the same clinical-context stratum, without a documented clinical contraindication or a patient-driven constraint. Target windows should be defined using a prespecified hierarchial approach: (1) existing local, executable service-level agreements when available; (2) guideline- or consensus-based time anchors translated into operational thresholds; and (3) when neither provides a usable anchor, a provisional window derived from baseline operational performance (e.g., pre-deployment P75/P90), with updates versioned and governed under MFAS change control. Each over-window interval receives one primary auditable E-code (Supplementary Box S2) during routine MFAS huddles; E1–E2 are treated as non-avoidable by default, recurrent E0/E4/E5 patterns trigger a time-bound corrective action entry (owner, lever, deadline, verification metric), and E6 is tracked as a data/information technology quality event requiring remediation to restore auditability. We operationalize delay using shared anchors mapped to the chain: trigger-to-activation, trigger-to-first qualified assessment, trigger-to-resource-ready (blood/OR/ICU/transfer readiness), and referral-completion delay, where applicable (13).

Target-setting guardrails to avoid institutionalizing inequity and to enable revision without obscuring gaps. When local baseline performance is used (e.g., pre-deployment P75/P90), it must be treated as a feasibility and capacity-planning input—not as a normative equity benchmark—because baseline workflows may already embed structural inequities. We therefore recommend a two-tier target structure reported in parallel for each interval: (i) an aspirational clinical anchor (derived from guideline intent, harm physiology, or cross-site best achievable performance, even if approximate), and (ii) a current capability target used for operational ramp-up. Critically, the current capability target must not be set solely by “what the baseline already delivers”; instead, it should be tied to a time-bounded improvement plan with explicit owners, controllable levers, and a prespecified ratchet schedule toward the clinical anchor (e.g., quarterly tightening). To prevent target revision from masking persistent inequities, routine reporting should (a) show side-by-side performance against both targets and (b) display absolute gap trajectories between strata (minutes/percentage points), not only whether each stratum “meets” a threshold. Sites should not systematically set looser targets for specific groups unless there is an ethical, clinically justified, and auditable rationale that is documented and subject to review. Any target modification must be versioned and accompanied by a re-audit to test whether gaps narrow without externalizing risk to safety or workload. Illustrative example (PPH): A site may define a trigger-to-activation clinical anchor of P90 ≤ 30 min, while adopting an interim capability target of P90 ≤ 45 min for the next 90 days during ramp-up, coupled to a ratcheting plan (e.g., ≤40 min next quarter and ≤35 min the quarter after) and named levers (e.g., timer ownership, auto-paging rules, and blood/OR readiness workflows).

Mechanisms should be treated as auditable. Data availability gaps arise when monitoring, documentation, or access to prior records differ across sites, shifting who triggers and when (15, 16). Workflow and capacity constraints—night shifts, crowding, and blood bank or operating room bottlenecks—can convert equal protocols into unequal waits (13, 17). Communication and advocacy gaps, including language discordance and limited social support, can shape escalation persistence and referral completion even when physiology is similar (6). AI can amplify these seams unless governance explicitly treats them as deployment targets (16).

To keep equity auditing feasible while preserving comparability, we recommend a small, auditable stratification set comprising (1) pregnancy phase (antenatal, intrapartum, and postpartum) (18); (2) baseline acuity at trigger (a low-burden severity marker captured at or immediately after T1) (19); (3) entry pathway (direct presentation, in-hospital deterioration, and interfacility transfer) (20); (4) geography/transfer proxy (catchment category or transfer-distance band; rurality where available) (21); and (5) access-to-care and communication-access proxies mapped to locally auditable fields—where available, payer/authorization status or self-pay as an administrative access proxy (22); and such data are not available or not meaningful, referral acceptance/transfer coordination steps, documentation completeness, rurality/travel-time bands, or other locally auditable administrative barriers, together with preferred language and interpreter need as communication-access indicators (23).

MFAS operationalizes equity as chain-of-care performance rather than model accuracy alone (13). Timestamp anchors and operational definitions (T1–T5) are provided in Box 2 (field-level EHR variants in Supplementary Table S2).

MFAS affects equity only when each metric is explicitly bound to a controllable lever and a named owner (6, 7). If a response is delayed, timer ownership, auto-paging rules, and mandatory senior-review triggers should be defined. If resources do not arrive within target windows, cross-service prioritization rules across the blood bank, OR, and ICU should be implemented and published, and all log overrides (including who acted and why) should be recorded so that rationing is reviewable. If transfers fail, closed-loop transfer tracking with escalation should be deployed when no accepting bed is secured within the defined window, without delaying bedside stabilization and reassessment. Examples of lever-to-metric mapping are provided in Supplementary Box S3.

Gaps should be displayed as absolute differences (minutes; percentage points), relative ratios, and pre/post run charts or statistical process control charts linked to specific workflow changes (24). p-values should be avoided as the headline metric; interpretability and actionability should be prioritized. Denominators should be kept stable and configuration changes should be annotated. Versioning and change control should be applied to model inputs, thresholds, alert routing, and workflow rules because configuration shifts can redistribute delays and resources in practice (14). Equity drift should be treated as a patient-safety risk: a baseline should be established before go-live, continuous monitoring should be conducted after launch, and the tool should be downgraded, rolled back, or disabled if harms or widening gaps emerge (6).

Minimum governance includes role-based access; immutable logs for model outputs, overrides, and pathway activations; and auditable system interfaces aligned with responsible-AI guidance and risk-management expectations. A minimum auditable artifact set is summarized in Supplementary Box S1 (16, 25). To ensure measurement low-burden and comparable across sites, a minimal, implementation-ready data-capture template (including required fields and timestamp definitions) is provided in Supplementary Appendix S2.

For PPH, bottlenecks tend to cluster around blood products (ordering, release, and transport), hemorrhage-control devices, rapid access to the OR or interventional radiology, anesthesia availability, and activation of massive transfusion pathways (1, 8, 10). Hypertensive crises/eclampsia require timely administration of magnesium sulfate and intravenous antihypertensives with continuous monitoring, supported by monitored-bed capacity and rapid escalation to higher-acuity monitoring or transfer when neurologic risk escalates (3, 13). Obstetric sepsis depends on a reliable screen-to-confirm sequence, prompt culture collection and laboratory testing, timely antimicrobials and resuscitation, and escalation pathways; ICU capacity and transfer logistics remain recurrent constraints (4, 11).

This worked example demonstrates how stratified delay gaps are interpreted with explicit exception coding and converted into accountable corrective actions and balancing measures, as discussed in the next section.

A predictable concern is that lowering thresholds or broadening triggers in the name of equity could increase false alarms, consume scarce OR/ICU/blood capacity, and worsen overall outcomes through crowding and mis-prioritization (26–28). MFAS treats this as a design constraint rather than a trade-off to be dismissed. First, MFAS audits equity on chain performance conditional on comparable presenting risk, not on raw trigger counts; any trigger expansion must therefore be paired with explicit resource-prioritization rules and surge plans (29). Second, MFAS binds stratified gaps to actionable levers: when delays shift from missed triggers to capacity constraints, the appropriate response is capacity governance (E3), rather than progressively expanding alerting thresholds (29). Third, MFAS prevents performative reporting by requiring versioned change control, override review, and a corrective-action register with named owners, deadlines, and verification metrics (30). Equity, therefore, becomes routine quality control—reducing avoidable delay without externalizing risk to safety, workload, or other patients.

MFAS governance requires cross-department ownership—obstetrics, anesthesia, ICU, blood bank, quality/safety, and health information technology (with data science support as needed)—to prevent an accountability vacuum in which a vendor “owns” the algorithm while clinicians own the consequences (6). A minimal cadence is sufficient: a monthly MFAS dashboard huddle reviews stratified run charts by chain link and assigns owners for clusters of over-window intervals; a quarterly cross-service review reassesses target windows, routing rules, and capacity plans; and sentinel events trigger rapid reconstruction of timestamps and immediate containment actions (14).

Transparency should be practical. Patients and families should receive a plain-language written explanation that the system is designed to support timely response—not to deny care—with a correction/appeal pathway when data are missing or an escalation decision is disputed (6, 16).

Patient-facing example text: “We use an electronic alert to help the care team respond quickly when time-critical pregnancy or postpartum complications are suspected. The alert supports timely assessment and escalation and does not replace clinician judgment or deny care. If you believe key information was missing or escalation was delayed, please ask the bedside team to review the alert record and escalation steps.” Correction/appeal pathway: (1) a bedside review of the alert and timeline; (2) submission of a data-correction ticket within 24–48 h if documentation/logs are incomplete; (3) a service-lead review of MFAS timestamps/E-code within 7 days if escalation is disputed; (4) document actions in the audit-to-action register and provide a brief written summary to the patient/family. Internally, transparency requires acknowledgment and override logs so that “who acted and why” remains visible for post-event learning and accountability (16).